Welcome to our dedicated page for SHUTTLE PHARMACTCLS HLDGS SEC filings (Ticker: SHPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech like Shuttle Pharmaceuticals means wading through pages of radiation-sensitizer chemistry, trial protocols, and financing footnotes. If finding R&D burn rates or decoding licensing terms inside a 10-K feels overwhelming, you鈥檙e not alone.
Stock Titan solves that problem. Our AI surfaces the numbers and narrative that matter鈥攃ash runway, Phase 2 milestones, dilution risks鈥攄irectly from every filing type. Need the Shuttle Pharmaceuticals annual report 10-K simplified? We highlight how Ropidoxuridine鈥檚 glioblastoma study influences revenue projections. Curious about a fresh capital raise? The latest Shuttle Pharmaceuticals 8-K material events explained appear with plain-English context the moment EDGAR posts.
Here鈥檚 what you鈥檒l find on this page:
- AG真人官方-time alerts for Shuttle Pharmaceuticals Form 4 insider transactions real-time, so you can see when executives buy or sell shares.
- Concise AI notes inside every Shuttle Pharmaceuticals quarterly earnings report 10-Q filing, turning trial-cost tables into readable trends.
- Side-by-side comparisons of equity issuances, royalty obligations, and Shuttle Pharmaceuticals proxy statement executive compensation disclosures.
Whether you鈥檙e monitoring Shuttle Pharmaceuticals insider trading Form 4 transactions before a data read-out or seeking a quick Shuttle Pharmaceuticals earnings report filing analysis, our platform answers the exact questions professionals ask: 鈥渦nderstanding Shuttle Pharmaceuticals SEC documents with AI鈥�. All filings, all the time鈥攅xplained simply.
Shuttle Pharmaceuticals Holdings has filed a Form D notice for an exempt securities offering under Rule 506(b). The company has successfully raised $4,250,000 through the offering, which was completed on June 20, 2025, with no remaining amount to be sold.
Key details of the offering:
- Securities offered include equity, options/warrants, and securities to be acquired upon exercise
- WestPark Capital served as broker-dealer with sales commissions of $170,000
- Total of 1 investor participated in the offering
- Offering not intended to last more than one year
The company's leadership includes Christopher Cooper (CEO), Peter Dritschilo (President/COO), Mira Jung (Chief Scientific Officer), Tyvin Rich (Chief Medical Officer), and Timothy Lorber (CFO). The pharmaceutical company is headquartered in Gaithersburg, Maryland, and was incorporated in Delaware over five years ago.
Shuttle Pharmaceuticals Holdings (NASDAQ:SHPH) has entered into a private placement agreement with an accredited investor on June 20, 2025. The company will sell 21,924 shares of common stock at $3.60 per share and 1,158,953 pre-funded warrants at $3.599 per warrant with a $0.001 exercise price.
The agreement includes a registration rights requirement to file within 10 days and achieve effectiveness within 90-120 days. The company and insiders agreed to a 60-day lock-up period. WestPark Capital served as placement agent, receiving a 4% fee of gross proceeds plus expense reimbursement.
FAQ
What is the current stock price of SHUTTLE PHARMACTCLS HLDGS (SHPH)?
What is the market cap of SHUTTLE PHARMACTCLS HLDGS (SHPH)?
What is the primary focus of Shuttle Pharmaceuticals Holdings Inc?
How does Shuttle Pharmaceuticals aim to improve cancer treatments?
What is Ropidoxuridine (IPdR) and its role in the company鈥檚 pipeline?
How are the HDAC inhibitors significant in Shuttle Pharma's research?
What distinguishes Shuttle Pharmaceuticals in the competitive oncology sector?
What clinical trials is the company currently conducting?
Why is radiation therapy central to their treatment strategy?
How does Shuttle Pharma ensure scientific rigor in its research?
